US Bancorp
SMMT icon

US Bancorp’s Summit Therapeutics SMMT Stock Holding History

US Bancorp’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$338K Buy
23,219
+21,369
+1,155% +$379K ﹤0.01% 1825
2026
Q1 		$35.1K Buy
1,850
+1,525
+469% +$24.7K ﹤0.01% 2858
2025
Q4 		$5.68K Sell
325
-356
-52% -$6.7K ﹤0.01% 3488
2025
Q3 		$14.1K Buy
681
+333
+96% +$8.07K ﹤0.01% 3207
2025
Q2 		$7.41K Buy
348
+220
+172% +$5.02K ﹤0.01% 3522
2025
Q1 		$2.47K Sell
128
-35
-21% -$702 ﹤0.01% 3831
2024
Q4 		$2.91K Buy
+163
New +$3.16K ﹤0.01% 3777
2021
Q4 		– Sell
-339
Closed -$2K – 4215
2021
Q3 		$2K Sell
339
-887
-72% -$6.37K ﹤0.01% 3917
2021
Q2 		$9K Sell
1,226
-572
-32% -$3.75K ﹤0.01% 3453
2021
Q1 		$10K Buy
1,798
+1,582
+732% +$10.2K ﹤0.01% 3296
2020
Q4 		$1K Buy
+216
New +$915 ﹤0.01% 3703

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

US Bancorp's SMMT Position: Q2 2026 in Review

US Bancorp increased its Summit Therapeutics (SMMT) stake by 1,155% in Q2 2026, buying an estimated $379K and bringing the position to 23,219 shares worth $338K. The position accounts for ﹤0.01% of the portfolio, ranked #1825.

US Bancorp first reported a position in SMMT in Q4 2020 and has held it in 11 quarters since. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • US Bancorp held 23,219 shares of Summit Therapeutics worth $338K as of Q2 2026.
  • US Bancorp bought 21,369 Summit Therapeutics shares in Q2 2026, an estimated $379K.
  • Summit Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #1825 holding.
  • US Bancorp first reported a position in Summit Therapeutics in Q4 2020 and has held it in 11 quarters since.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.